We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical
RARE

274 hedge funds and large institutions have $3.63B invested in Ultragenyx Pharmaceutical in 2024 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 117 increasing their positions, 80 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 3 → 6 (+3)

52% more call options, than puts

Call options by funds: $22.7M | Put options by funds: $15M

46% more repeat investments, than reductions

Existing positions increased: 117 | Existing positions reduced: 80

18% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 40

2% more funds holding

Funds holding: 269 → 274 (+5)

0.33% more ownership

Funds ownership: 97.06% → 97.4% (+0.33%)

3% less capital invested

Capital invested by funds: $3.73B → $3.63B (-$103M)

Holders
274
Holders Change
+5
Holders Change %
+1.86%
% of All Funds
3.96%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.09%
New
47
Increased
117
Reduced
80
Closed
40
Calls
$22.7M
Puts
$15M
Net Calls
+$7.77M
Net Calls Change
-$6.85M

Top Buyers

1
VPC
Vestal Point Capital
New York
+$72.2M
2
Sands Capital Management
Sands Capital Management
Virginia
+$63.8M
3
Millennium Management
Millennium Management
New York
+$48.8M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$46.1M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$41.6M

Top Sellers

1
RI
RTW Investments
New York
-$163M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$24.6M
3
Pictet Asset Management
Pictet Asset Management
Switzerland
-$20.5M
4
EAM
Eventide Asset Management
Massachusetts
-$16.8M
5
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
-$9.75M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACA
26
Avoro Capital Advisors
New York
$34.1M – – –
Bank of New York Mellon
27
Bank of New York Mellon
New York
$32.1M -$5.54M -129,713 -14%
SSA
28
Schonfeld Strategic Advisors
New York
$29.5M +$11.8M +276,149 +63%
CS
29
Candriam SCA
Luxembourg
$28.3M +$7.32M +171,345 +33%
Fidelity Investments
30
Fidelity Investments
Massachusetts
$26.6M -$5.74M -134,414 -17%
Jacobs Levy Equity Management
31
Jacobs Levy Equity Management
New Jersey
$26.1M -$2.28M -53,292 -8%
Goldman Sachs
32
Goldman Sachs
New York
$25.9M +$11.3M +265,392 +73%
Man Group
33
Man Group
United Kingdom
$25.8M +$20.3M +475,085 +309%
Two Sigma Investments
34
Two Sigma Investments
New York
$23.4M +$6.53M +152,995 +37%
Pictet Asset Management
35
Pictet Asset Management
Switzerland
$22.9M -$20.5M -479,556 -46%
FAM
36
Fred Alger Management
New York
$22.6M -$1.39M -32,646 -6%
Bank of America
37
Bank of America
North Carolina
$22.5M +$5.01M +117,282 +27%
Point72 Asset Management
38
Point72 Asset Management
Connecticut
$22.2M +$20.4M +478,849 +786%
Charles Schwab
39
Charles Schwab
California
$22.1M +$2.27M +53,235 +11%
DCM
40
Driehaus Capital Management
Illinois
$21.7M +$5.93M +138,889 +36%
EHI
41
Eagle Health Investments
Connecticut
$21.6M +$9.6M +224,800 +75%
Morgan Stanley
42
Morgan Stanley
New York
$20.5M -$274K -6,413 -1%
EA
43
Emerald Advisers
Pennsylvania
$20M -$62.2K -1,456 -0.3%
Two Sigma Advisers
44
Two Sigma Advisers
New York
$18.2M -$256K -6,000 -1%
Axa
45
Axa
France
$17.5M +$3.95M +92,567 +28%
FLSM
46
Frazier Life Sciences Management
California
$17.5M +$18.1M +425,000 New
Hudson Bay Capital Management
47
Hudson Bay Capital Management
Connecticut
$17.1M +$4.69M +109,900 +36%
GKIM
48
GW&K Investment Management
Massachusetts
$16.7M +$4.4M +103,142 +34%
Walleye Capital
49
Walleye Capital
New York
$16.1M +$5.29M +123,951 +46%
EMFAT
50
Emerald Mutual Fund Advisers Trust
Pennsylvania
$16.1M +$221K +5,184 +1%
1
2
3 4 5

RARE Hedge Fund Activity: Q2 2024 in Review

274 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q2 2024, worth a combined $3.63B — down 2.8% from $3.73B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new RARE positions and 40 closed out — a net gain of 7 holders — while 117 added to existing stakes and 80 trimmed.

The largest buyer was Vestal Point Capital, adding an estimated $72.2M. The largest seller was RTW Investments, cutting an estimated $163M.

  • 274 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q2 2024, up from 269 in Q1 2024.
  • Funds reported $3.63B of Ultragenyx Pharmaceutical stock for Q2 2024, down 2.8% quarter-over-quarter.
  • 47 funds opened new Ultragenyx Pharmaceutical positions in Q2 2024 and 40 closed out, a net change of +7 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q2 2024 was Vestal Point Capital, an estimated $72.2M added.
  • The largest Ultragenyx Pharmaceutical seller in Q2 2024 was RTW Investments, an estimated $163M sold.

Based on aggregated 13F filings for Q2 2024.